Pfizer's $16 Billion Purchase|of Hospira Cleared by FTC

WASHINGTON (CN) – Pfizer will sell off rights to four drugs to clear its $16 billion acquisition of Hospira of antitrust concerns, the FTC said in a settled complaint.     Pfizer will divest itself of assets and rights to its generic acetylcysteine inhalation solution, and to three injectable Hospira drugs: clindamycin phosphate, an antibiotic; voriconazole, an anti-fungal drug; and melphalan hydrochloride, a chemotherapy drug. All four come in branded and generic versions.     Alvogen, a U.S.-based generic drugmaker, is expected to buy rights to all the drugs.     The companies will have three years to complete the divestitures.